Comparative summary of Fc-modified monospecific ABs, checkpoint-targeting bsABs, and conjugate or tumor-restricted PD-1/PD-L1 ABs: mechanistic advantages and practical trade-offs. This evidence concerns the gene CD274 and neoplasm.